Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...
A preoperative trial shows that activating the progesterone receptor with low-dose megestrol can deepen estrogen blockade and curb tumor proliferation, without added toxicity, pointing to a simpler ...
Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis. This is an ASCO ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
A 55 year old female patient underwent MRI guided biopsy for a non-mass enhancement. She has previously biopsy-proven ipsilateral breast carcinoma. What is the most likely immunohistochemical profile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results